The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10109 malaria professionals are enjoying the free benefits of MalariaWorld today

coartem

Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria

March 29, 2011 - 07:35 -- Kabogo Ndegwa
Author(s): 
Gilbert Lefèvre, Anne Claire Marrast, Heiner Grueninger
Reference: 
Annals of the New York Academy of Sciences Volume 1222, Pharmaceutical Science to Improve the Human Condition: Prix Galien 2010 pages 19–29, March 2011

Despite considerable advances in the treatment and prevention of malaria, Plasmodium falciparum is still a threat to millions of people across the world, particularly in sub-Saharan Africa, with infants and young children bearing the greatest burden in terms of morbidity and mortality.

Medical Condition: 
Medical Treatment: 

Clinical Microbiology: Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus®) versus artemether-lumefantrine (Coartem®) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast

April 13, 2010 - 09:48 -- Kabogo Ndegwa
Author(s): 
Babacar Faye, André Touré Offianan, Jean Louis Ndiaye, Roger Clement Tine, Walatchin Touré, Kali Djoman, Khadime Sylla, Paulette Suzanne Ndiaye, Louis Penali, Oumar Gaye
Reference: 
Tropical Medicine & International Health, Volume 15, Issue 5, May 2010, Pages: 608-613

This study demonstrates the efficacy and tolerability of AS + AQ for uncomplicated Plasmodium falciparum malaria treatment in African patients over the age of 7 years.

Medical Condition: 
Medical Treatment: 

Treatment with Coartem (Artemether-Lumefantrine) in Papua New Guinea

April 13, 2010 - 08:58 -- Patrick Sampao
Author(s): 
Sonja Schoepflin, Enmoore Lin, Benson Kiniboro, Jeana T. DaRe, Rajeev K. Mehlotra, Peter A. Zimmerman, Ivo Mueller, AND Ingrid Felger
Reference: 
American Journal of Tropical Medicine Hygiene, Vol 82 : 4, 2010, pp. 529-534

After excluding genetic host factors by genotyping potentially relevant cytochrome P450 loci, the high number of treatment failures in our study is best explained by poor adherence to complex dosing regimens in combination with insufficient fat supplementation, which are both crucial parameters for the outcome of Coartem treatment.

Medical Condition: 
Medical Treatment: 

Review: Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia

October 25, 2009 - 15:39 -- Bart G.J. Knols
Author(s): 
Karen I Barnes, Pascalina Chanda, Gebre Ab Barnabas
Reference: 
Malaria Journal 2009, 8(Suppl 1):S8 (12 October 2009)

 

Malaria can be controlled in endemic countries by using artemisinin-based combination therapy (ACT) in combination with indoor residual spraying (IRS) and insecticide-treated nets (ITNs). At least 40 malaria-endemic countries in sub-Saharan Africa now recommend the use of ACT as first-line treatment for uncomplicated falciparum malaria as a cornerstone of their malaria case management.

Medical Condition: 

Review: Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children

October 25, 2009 - 15:25 -- Bart G.J. Knols
Author(s): 
Salim Abdulla, Issaka Sagara
Reference: 
Malaria Journal 2009, 8(Suppl 1):S7 (12 October 2009)

 

Ahead of a call from WHO for child-friendly medicines, Novartis, working in partnership with Medicines for Malaria Venture (MMV), started the development of a new formulation of AL for infants and young children: Coartem® Dispersible. 

Medical Condition: 

Review: Safety profile of Coartem®: the evidence base

October 25, 2009 - 15:17 -- Bart G.J. Knols
Author(s): 
Catherine Falade, Christine Manyando
Reference: 
Malaria Journal 2009, 8(Suppl 1):S6 (12 October 2009)

This article reviews the comprehensive data on the safety and tolerability from over 6,300 patients who have taken artemether/lumefantrine (Coartem®) as part of Novartis-sponsored or independently-sponsored clinical trials.

Medical Condition: 

Review: The clinical efficacy of artemether/lumefantrine (Coartem®)

October 25, 2009 - 15:12 -- Bart G.J. Knols
Author(s): 
Michael Makanga, Srivicha Krudsood
Reference: 
Malaria Journal 2009, 8(Suppl 1):S5 (12 October 2009)

 Current World Health Organization (WHO) guidelines for the treatment of uncomplicated falciparum malaria recommend the use of artemisinin-based combination therapy (ACT). Artemether/lumefantrine is an ACT prequalified by the WHO for efficacy, safety and quality, approved by Swissmedic in December 2008 and recently approved by the USA FDA. Coartem® is a fixed-dose combination of artemether and lumefantrine.

 

Medical Condition: 

Review: Understanding the pharmacokinetics of Coartem®

October 25, 2009 - 15:03 -- Bart G.J. Knols
Tags: 
Author(s): 
Abdoulaye Djimdé, Gilbert Lefèvre
Reference: 
Malaria Journal 2009, 8(Suppl 1):S4 (12 October 2009)

In conclusion, knowledge of the pharmacokinetic profiles of artemether and lumefantrine is increasing within a range of settings, including infants and children. However, additional data would be warranted to better characterize artemether and lumefantrine pharmacokinetics in patients with hepatic impairment, in pregnant women, and in patients undergoing HIV/AIDS chemotherapy.

 

Technology: 
Medical Treatment: 

Review: Coartem®: the journey to the clinic

October 25, 2009 - 14:58 -- Bart G.J. Knols
Tags: 
Author(s): 
Zulfiqarali G Premji
Reference: 
Malaria Journal 2009, 8(Suppl 1):S3 (12 October 2009)

Artemisinin, from which the artemether component of Coartem®(artemether/lumefantrine, AL) is derived, is obtained from the plant sweet wormwood (Artemisia annua) which has been used for over 2,000 years as a Chinese herbal remedy. Artemisinin was first identified by Chinese researchers as the active anti-malarial constituent of A. annua and its derivatives were found to be the most potent of all anti-malarial drugs.

 

Medical Treatment: 

Introduction: Malaria management - progress made and challenges still to face

October 25, 2009 - 14:45 -- Bart G.J. Knols
Tags: 
Author(s): 
Bernhards R Ogutu
Reference: 
Malaria Journal 2009, 8(Suppl 1):S1 (12 October 2009)

This supplement reviews the contribution made by AL as an ACT to the tremendous progress made in the control of malaria and establishes effective treatment as a cornerstone in the foundation of effective, quality patient care for infants, children and adults with malaria.

Medical Treatment: 
Subscribe to RSS - coartem